<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/axonics-modulation-technologies-nasdaqaxnx-stock-price-down-7-1.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T16:25:54+00:00"/>
    <meta property="og:title" content="Axonics Modulation Technologies (NASDAQ:AXNX) Stock Price Down 7.1%"/>
    <meta property="og:description" content="Axonics Modulation Technologies Inc (NASDAQ:AXNX)’s stock price dropped 7.1% during mid-day trading on Monday . The stock traded as low as $26.63 and last traded at $24.85, approximately 15,160 shares changed hands during mid-day trading. A decline of 97% from the average daily volume of 443,608 shares. The stock had previously closed at $26.75. AXNX […]"/>
  </head>
  <body>
    <article>
      <h1>Axonics Modulation Technologies (NASDAQ:AXNX) Stock Price Down 7.1%</h1>
      <address><time datetime="2019-11-18T16:25:54+00:00">18 Nov 2019, 16:25</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Axonics Modulation Technologies Inc (NASDAQ:AXNX)’s stock price dropped 7.1% during mid-day trading on Monday . The stock traded as low as $26.63 and last traded at $24.85, approximately 15,160 shares changed hands during mid-day trading. A decline of 97% from the average daily volume of 443,608 shares. The stock had previously closed at $26.75.</p>
      <p>AXNX has been the subject of several recent research reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> lowered shares of Axonics Modulation Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Barclays started coverage on shares of Axonics Modulation Technologies in a research note on Monday, October 21st. They set an “overweight” rating and a $43.00 price objective on the stock. Bank of America upped their price objective on shares of Axonics Modulation Technologies from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Needham &amp; Company LLC reaffirmed a “buy” rating and set a $48.00 price objective on shares of Axonics Modulation Technologies in a research note on Tuesday, November 5th. Finally, Morgan Stanley upped their price objective on shares of Axonics Modulation Technologies from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Axonics Modulation Technologies currently has an average rating of “Buy” and a consensus target price of $40.40.</p>
      <p>The company has a debt-to-equity ratio of 0.18, a current ratio of 12.21 and a quick ratio of 11.51. The stock has a market capitalization of $828.34 million and a P/E ratio of -5.12. The company’s 50 day simple moving average is $23.24 and its two-hundred day simple moving average is $31.05.</p>
      <p>Axonics Modulation Technologies (NASDAQ:AXNX) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.14). The firm had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.45 million. Axonics Modulation Technologies had a negative return on equity of 51.55% and a negative net margin of 1,530.43%. The firm’s revenue for the quarter was up 555.0% compared to the same quarter last year. On average, research analysts anticipate that Axonics Modulation Technologies Inc will post -2.6 earnings per share for the current fiscal year.</p>
      <p>In other news, COO Rinda Sama sold 5,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.70, for a total transaction of $123,500.00. 35.99% of the stock is owned by corporate insiders.</p>
      <p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC bought a new stake in shares of Axonics Modulation Technologies during the second quarter valued at approximately $32,000. BNP Paribas Arbitrage SA bought a new stake in shares of Axonics Modulation Technologies during the second quarter valued at approximately $35,000. Bank of Montreal Can grew its stake in shares of Axonics Modulation Technologies by 963.7% during the second quarter. Bank of Montreal Can now owns 1,436 shares of the company’s stock valued at $58,000 after purchasing an additional 1,301 shares during the last quarter. AdvisorNet Financial Inc grew its stake in shares of Axonics Modulation Technologies by 130.2% during the second quarter. AdvisorNet Financial Inc now owns 2,302 shares of the company’s stock valued at $94,000 after purchasing an additional 1,302 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Axonics Modulation Technologies by 84.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,300 shares of the company’s stock valued at $94,000 after purchasing an additional 1,050 shares during the last quarter. 33.23% of the stock is currently owned by institutional investors and hedge funds.</p>
      <p><b>About Axonics Modulation Technologies</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/AXNX/">NASDAQ:AXNX</a>)</p>
      <p>Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/book-value-equity-per-share-bvps/">Book Value Per Share – BVPS</a></p>
    </article>
  </body>
</html>